These drugs have demonstrated their ability to induce or restore the process of autophagy, ameliorate hepatocyte steatosis, reduce inflammation caused by KCs, inhibit HSC activation, decrease the occurrence of liver fibrosis, and delay the progression of NAFLD (115). This evidence concerns the gene TBCE and metabolic dysfunction-associated steatotic liver disease.